A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Incyte Corporation
Eilean Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Turin, Italy
Novartis
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Prelude Therapeutics
University of Southern California
Italfarmaco
University Hospital, Brest
Novartis
University of Washington
M.D. Anderson Cancer Center
University of California, Irvine
Disc Medicine, Inc
Chengdu Zenitar Biomedical Technology Co., Ltd
Peking Union Medical College Hospital
Ono Pharmaceutical Co. Ltd
Brigham and Women's Hospital
Ionis Pharmaceuticals, Inc.
Hospices Civils de Lyon
M.D. Anderson Cancer Center
Massachusetts General Hospital
University of Miami
M.D. Anderson Cancer Center
Silence Therapeutics plc
Icahn School of Medicine at Mount Sinai
University Hospital, Angers
Thomas Jefferson University
Thomas Jefferson University
Ohio State University Comprehensive Cancer Center
PharmaEssentia Japan K.K.
Incyte Corporation
Hangzhou GluBio Pharmaceutical Co., Ltd.
PharmaEssentia
Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc.
PharmaEssentia
PharmaEssentia
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Barbara Ann Karmanos Cancer Institute
Roswell Park Cancer Institute
City of Hope Medical Center
RWTH Aachen University
BeBetter Med Inc
M.D. Anderson Cancer Center